C6 Ceramide Dramatically Increases Vincristine Sensitivity Both In Vivo And In Vitro, Involving Amp-Activated Protein Kinase-P53 Signaling

Min-Bin Chen,Qin Jiang,Yuan-Yuan Liu,Yan Zhang,Bang-Shun He,Mu-Xin Wei,Jian-Wei Lu,Yong Ji,Pei-Hua Lu

DOI: https://doi.org/10.1093/carcin/bgv094

2015-01-01

Carcinogenesis

Abstract:Use of the conventional cancer chemotherapy (i.e. vincristine) is limited in tumor cells exhibiting pre-existing or acquired resistance. Here, we found that C6 ceramide (C6) dramatically sensitized vincristine's activity. In vitro, C6 and vincristine coadministration induced substantial necrosis and apoptosis in multiple human cancer cell lines, which were accompanied by a profound AMP-activated protein kinase (AMPK) activation, subsequent p53 activation, mTORC1 inactivation and Bcl-2/HIF-1 alpha downregulation. Such synergistic effects were attenuated by AMPK inactivation through genetic mutation or short hairpin RNA silencing. Coadministration-activated p53 translocated to mitochondria, and formed a complex with cyclophilin-D, leading to mitochondrial permeability transition pore opening and cell necrosis. Disrupting p53-Cyp-D complexation through pharmacological or genetic means reduced costimulation-induced cytotoxicity. In vivo, a liposomal C6 was synthesized, which dramatically enhanced the antiproliferative activity of vincristine on HCT-116 or A2780 xenografts. Together, C6 sensitizes vincristine-induced anticancer activity in vivo and in vitro, involving activating AMPK-p53 signaling.